Where does Alpha Tau Medical Ltd. rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Alpha Tau Medical Ltd. ranks #13,293 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Alpha Tau Medical Ltd. hold?

Alpha Tau Medical Ltd. holds 22 US utility patents granted between 2018 and 2025, spanning 12 technology areas.

What is Alpha Tau Medical Ltd.'s Innovation Score?

Alpha Tau Medical Ltd. has an Innovation Score of 53.8 out of 100 (top 8% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

What technology areas does Alpha Tau Medical Ltd. focus on?

Alpha Tau Medical Ltd.'s top technology area is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy) with 22 patents, ranking #162 of 1,943 assignees active in that subclass. Grants appear in 12 CPC subclasses total.

Is Alpha Tau Medical Ltd.'s patent grant rate increasing or decreasing?

Alpha Tau Medical Ltd.'s recent grant velocity is +1600% compared to the prior five-year period (grant years, not application filing dates). This indicates accelerating grant output.

What does claim depth mean for Alpha Tau Medical Ltd.'s patents?

Alpha Tau Medical Ltd.'s patents average 17.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Alpha Tau Medical Ltd. patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Alpha Tau Medical Ltd.

USPTO PatentsView assignee record - 22 granted patents across 12 technology areas, recorded in grant years 2018–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Alpha ranks #13,293 of 49,997 tracked US assignees by granted-patent volume, with 22 patents across 12 technology areas.

#13,293
of 49,997 US assignees by volume: Top 8%
by Innovation Score (53.8/100): 17.9
avg claims per patent: +1600%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R13293 · Foreign Corporation #13,293 · 22 grants

GRANTS-SMALL · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-PAR · CLAIMS-RICH · TYPE-FRNCORP · VEL-SURGE · BOOK-FULL

GRANTS-SMALL 22 grants
MID-PACK #13,293/49,997
PHOTO-FINISH Agama-X
CPC-FOCUS A61N · 12 areas
INNOV-PAR 53.8/100
CLAIMS-RICH 17.9 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-SURGE +1600% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Agama-X Co., Ltd. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Alpha’s 53.8 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.8 pts (20%) Velocity 20.0 pts (37%) Breadth 12.2 pts (23%) Claim depth 10.7 pts (20%)

Qualcomm Incorporated · highest

85
Alpha Tau Medical · this assignee

54
3D Lighting… · lowest

7

What this shows Alpha's Innovation Score is 53.8/100 (top 8% of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Alpha?

Each dot is one of Alpha’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Alpha’s own 17.9 claims/patent is ABOVE the 16.4 median for these volume peers. More thorough claims than most filers at this scale, not just more of them.

Alpha vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Alpha's grants concentrate

Alpha Tau Medical Ltd. is a focused PatentsView assignee: 12 CPC subclasses with 100% of grants classified under A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy). Peak complete grant year is 2024 (14 grants) versus a trough of 1 in 2018. By volume, Alpha sits between Agama-X Co., Ltd. and Applied Nanostructured Solutions, LLC.

Alpha's three-year grant acceleration

Alpha Tau Medical Ltd. shows 17 grants in 2022–2024 against only 0 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Agama-x

22
Airbus Group Indi…

22
Airship Group

22
Alcatel-lucent Sh…

22
Altus Interventio…

22
Anhui Agricultura…

22
Anthrogenesis

22
Applied Nanostruc…

22
Alpha Tau Medical ◀

22

What this shows Alpha holds 22 patents at rank #13,301, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Alpha

By rank, the assignees closest to #13,301 in granted patent volume.

Leaders in A61N (Electrotherapy)

Other assignees with the most granted patents in Alpha's primary technology class.

Alpha's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

54 Top 8% higher than 92% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2018–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2018–2019 baseline. Full figures in the table below.

View data table

Alpha Tau Medical Ltd. patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2018	1	4.5%
2022	1	4.5%
2023	2	9.1%
2024	14	63.6%
2025partial year	4	18.2%

Which technologies does Alpha Tau Medical Ltd. patent most?

A61N - ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy 22

A61K - Preparations FOR Medical, Dental OR Toiletry Purposes 5

A61L - Methods OR Apparatus FOR Sterilising Materials OR Objects IN GENERAL; Disinfection, Sterilisation OR Deodorisation OF AIR; Chemical Aspects OF Bandages, Dressings, Absorbent Pads OR Surgical ARTICLES; Materials FOR Bandages, Dressings, Absorbent Pads OR Surgical Articles 3

A61B - DIAGNOSIS; SURGERY; Identification 3

G16H - Healthcare Informatics, i.e. Information AND Communication Technology [ICT] Specially Adapted FOR THE Handling OR Processing OF Medical OR Healthcare Data 2

G21G - Conversion OF Chemical ELEMENTS; Radioactive Sources 2

A61P - Specific Therapeutic Activity OF Chemical Compounds OR Medicinal Preparations 2

B05D - Processes FOR Applying Fluent Materials TO Surfaces, IN General 2

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 1

G21F - Protection Against X-radiation, Gamma Radiation, Corpuscular Radiation OR Particle BOMBARDMENT; Treating Radioactively Contaminated MATERIAL; Decontamination Arrangements Therefor 1

C23C - Coating Metallic MATERIAL; Coating Material With Metallic MATERIAL; Surface Treatment OF Metallic Material BY Diffusion Into THE Surface, BY Chemical Conversion OR SUBSTITUTION; Coating BY Vacuum Evaporation, BY Sputtering, BY ION Implantation OR BY Chemical Vapour Deposition, IN General 1

G01T - Measurement OF Nuclear OR X-radiation 1

Top 12 of 12 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Alpha Tau Medical Ltd.'s patent record in context - here's where to go next.

Alpha Tau Medical Ltd.'s lead technology class is A61N (ELECTROTHERAPY; MAGNETOTHERAPY; Radiation THERAPY; Ultrasound Therapy), 100% of its portfolio - see every assignee active in that class. Explore A61N
Ranked #13,293 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Alpha Tau Medical Ltd. against Agama-X Co., Ltd., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 53.8/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent, US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.